Skip to main content

Incannex Healthcare Inc.

corporate_fare Company Profile

Incannex Healthcare Inc.

IXHL·NASDAQ·Life Sciences·CIK 0001873875

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. The company's primary development focus is IHL-42X for obstructive sleep apnea (OSA). They are also evaluating the next clinical development plan for PSX-001 in generalized anxiety disorder (GAD) and the potential for further development of IHL-675A in inflammatory conditions. The goal is to provide additional treatment options for patients whose needs are not adequately met by existing care. IHL-42X, the lead drug candidate for OSA, is an oral fixed-dose combination of dronabinol and acetazolamide. This combination is designed to work synergistically by targeting two different physiological pathways linked to the intermittent hypoxia and hypercapnia characteristic of OSA. The company completed the Phase 2 portion of its RePOSA Phase 2/3 clinical trial in July 2025, which showed that IHL-42X reduced apnea hypopnea index (AHI), improved patient-reported outcomes, and was well-tolerated in OSA patients. In December 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for IHL-42X for OSA treatment. Incannex Healthcare Inc. is conducting an additional dose confirmation study, the DReAMzz Study, to optimize the ratio of dronabinol and acetazolamide before advancing to a Phase 3 clinical trial for IHL-42X. The DReAMzz Study is a Phase 2 dose confirmation crossover trial evaluating nine dose combinations of IHL-42X across approximately 120 subjects at 14 U.S. clinical sites. This study started in May 2026, began screening participants in July 2026, is currently enrolling participants, and is estimated to be completed in mid-2027. Results from the DReAMzz Study are expected to inform the design of a planned Phase 3 clinical trial for IHL-42X. PSX-001, another lead drug candidate in clinical development after completing a Phase 2 trial, is an oral synthetic psilocybin treatment administered with psychological therapy for patients with moderate-to-severe GAD.

Incannex Healthcare Inc. (NASDAQ:IXHL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for IXHL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Incannex Healthcare Finalizes $10 Million Direct Offering with Warrants, Securing Critical Capital
  • Incannex Healthcare Prices $10M Registered Direct Offering at Premium, Securing Funds for IHL-42X Phase 2 Study
  • Incannex Terminates ATM After $108.4M Raise; Lead Drug IHL-42X Earns FDA Fast Track Designation
  • Incannex Healthcare Announces 1-for-30 Reverse Stock Split to Regain Nasdaq Compliance
  • Incannex Healthcare Secures $71.66M Capital Infusion, Boosting Liquidity Despite Increased Losses and Persistent Control Weakness

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$0
Net Income
-$19.3M
Diluted EPS
-$1.66
Op. Cash Flow
-$12.87M
Free Cash Flow
-$12.88M
Operating Income
-$23.03M
Cash & Equivalents
$67.71M
Debt / Equity
0.00×
Shares Outstanding
12.54M sh
Source: 10-K · filed 2026-09-25 · accession 0001628280-26-063506
$1.91 +2.60% today
52-week range · as of 2026-11-12 $1.91 – $14.91
Market cap
$23.34M
Volume
220.7K (2.2× avg)
3-mo avg 101.2K
Live data · 2026-11-22 05:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IXHL - Filings & News (Page 2)

IXHL
Mar 12, 2026, 4:17 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $1.91 info
Change: -$1.28 (-40%) info
Market Cap: $23.336M info
IXHL
Mar 12, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.79
Real-time Price: $1.91 info
Change: -$2.88 (-60%) info
Market Cap: $23.336M info
IXHL
Mar 12, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.76
Real-time Price: $1.91 info
Change: -$4.85 (-72%) info
Market Cap: $23.336M info
IXHL
Feb 25, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2762
Real-time Price: $1.91 info
Change: Reverse Stock Split info
Market Cap: $23.336M info
IXHL
Feb 13, 2026, 7:48 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2751
Real-time Price: $1.91 info
Change: Reverse Stock Split info
Market Cap: $23.336M info
IXHL
Jan 29, 2026, 8:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3185
Real-time Price: $1.91 info
Change: Reverse Stock Split info
Market Cap: $23.336M info
IXHL
Jan 22, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3566
Real-time Price: $1.91 info
Change: Reverse Stock Split info
Market Cap: $23.336M info
IXHL
Jan 14, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3831
Real-time Price: $1.91 info
Change: Reverse Stock Split info
Market Cap: $23.336M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets